Navigation Links
Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Date:4/10/2008

p>As of February 29, 2008, the Company had approximately $4.2 million in available cash, cash equivalents, marketable securities and other investments. The Company had no long-term debt at the end of the quarter.

On November 1, 2007 Cryo-Cell commercially launched the C'elle menstrual stem cell preservation and storage service, an innovative and proprietary new service based on the Company's extensive patent portfolio of intellectual property. C'elle represents a major milestone in the Company's strategic plan to achieve product diversification, and the new service is expected to contribute to future revenue growth and earnings. In parallel, Cryo-Cell is also implementing plans to license C'elle technology in strategic global markets that may potentially serve to generate additional new sources of revenue.

"We are encouraged by Cryo-Cell's improved performance in the first quarter of 2008. In accordance with our long-term strategic plan, we believe that the Company is progressing well in the early phase of fiscal 2008," stated Mercedes Walton, Chairman and Chief Executive Officer. "In 2006, following nine consecutive quarters of profitability spanning the first quarter of 2004 through the second quarter of 2006, Cryo-Cell's Board of Directors made the deliberate decision to forsake continued near-term profitability in order to invest in the long-term growth of our business. At this juncture, we are pleased with early indicators that we believe reflect growing interest in C'elle, as both a standalone direct-to-consumer service and as a uniquely differentiated combination service offered along with our signature UCord(R) product."

"Notwithstanding formidable challenges associated with new product development, intensified industry competition and the overall impact of the economy on discretionary consumer spending, the Company has maintained a steadfast focus on our comprehensive strategic plan to achieve product diversification and advance commerc
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
5. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
6. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
8. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
9. MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
10. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
11. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Wis. - For the second time this year, a ... stock for sale to the public. Called an initial public ... to the companies and investors who are directly involved, but ... NimbleGen , a Madison-based biotechnology company, has filed papers with ...
... to experience high rates of failure. As a result, ... valued partner. The result stifles innovation, growth, and a ... requires shedding the flawed processes of yesterday, and introducing ... by promising incremental delivery of functional software. , , ...
... - Now that two companies he once owned ... strategy, Brian Wiegand's days as a self-described serial entrepreneur ... NameProtect , a developer of digital brand management ... of Wilmington, Del. , ,He will concentrate on ...
Cached Biology Technology:Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3Agile Revolution: A new era of software delivery 2Agile Revolution: A new era of software delivery 3Agile Revolution: A new era of software delivery 4NameProtect sold, tech entrepreneur to focus on Jellyfish.com 2
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... 20, 2010 TEL AVIV, Israel - European business ... leading platform for R&D-performing entrepreneurs and industries, will gather ... to take part in the first event in Israel ... Israel at the reigns of the EUREKA Network and ...
... and first use of a high-density SNP array for ... capable of revealing new insights into how the insect ... to findings published in the current edition of the ... the Anopheles gambiae genome can be used ...
... A child,s chances of developing allergies or wheezing is ... in the womb, according to scientists from the University of ... Research Council (MRC) and the British Lung Foundation, and undertaken ... in early pregnancy but falter later in pregnancy are likely ...
Cached Biology News:Israeli Minister of Industry and Trade to address European R&D leaders in Tel Aviv 2Genetic markers offer new clues about how malaria mosquitoes evade eradication 2Genetic markers offer new clues about how malaria mosquitoes evade eradication 3Allergies and wheezing illnesses in childhood may be determined in the womb 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
...
Request Info...
Request Info...
Biology Products: